Quality of life in ICON7: Need for patients' perspectives

The Lancet Oncology

Volumn 14, Issue 3, 2013, Pages 183-185

  Havrilesky, Laura J ^a   Abernethy, Amy P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PLATINUM COMPLEX;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; HUMAN; LETTER; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SURVIVAL TIME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG TOXICITY; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 84875240922     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70590-9     Document Type: Letter

References (8)

1. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365:2473-2483.
2. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496.
3. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012, 30:2039-2045.
4. Stark D, Nankivell M, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol 2013, published online Jan 18. http://dx.doi.org/10.1016/S1470-2045(12)70567-3.
5. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 2011, 29:89-96.
6. Cohn DE, Kim KH, Resnick KE, O'Malley DM, Straughn JM At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011, 29:1247-1251.
7. Meropol NJ, Egleston BL, Buzaglo JS, et al. Cancer patient preferences for quality and length of life. Cancer 2008, 113:3459-3466.
8. Zafar SY, Alexander SC, Weinfurt KP, Schulman KA, Abernethy AP Decision making and quality of life in the treatment of cancer: a review. Support Care Cancer 2009, 17:117-127.